JP2019526561A5 - - Google Patents

Download PDF

Info

Publication number
JP2019526561A5
JP2019526561A5 JP2019510788A JP2019510788A JP2019526561A5 JP 2019526561 A5 JP2019526561 A5 JP 2019526561A5 JP 2019510788 A JP2019510788 A JP 2019510788A JP 2019510788 A JP2019510788 A JP 2019510788A JP 2019526561 A5 JP2019526561 A5 JP 2019526561A5
Authority
JP
Japan
Prior art keywords
formulation
alkylene
composition
alkyl
carbon atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019510788A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019526561A (ja
JP6898429B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2017/098575 external-priority patent/WO2018036498A1/en
Publication of JP2019526561A publication Critical patent/JP2019526561A/ja
Publication of JP2019526561A5 publication Critical patent/JP2019526561A5/ja
Application granted granted Critical
Publication of JP6898429B2 publication Critical patent/JP6898429B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019510788A 2016-08-24 2017-08-23 黄斑変性症を治療するためのエンタカポン関連化合物 Active JP6898429B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2016/096472 2016-08-24
CN2016096472 2016-08-24
PCT/CN2017/098575 WO2018036498A1 (en) 2016-08-24 2017-08-23 Entacapone-related compounds to treat macular degeneration

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021013670A Division JP7116202B2 (ja) 2016-08-24 2021-01-29 黄斑変性症を治療するための医薬の製造におけるエンタカポン関連化合物の使用

Publications (3)

Publication Number Publication Date
JP2019526561A JP2019526561A (ja) 2019-09-19
JP2019526561A5 true JP2019526561A5 (https=) 2020-07-16
JP6898429B2 JP6898429B2 (ja) 2021-07-07

Family

ID=61245496

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019510788A Active JP6898429B2 (ja) 2016-08-24 2017-08-23 黄斑変性症を治療するためのエンタカポン関連化合物
JP2021013670A Active JP7116202B2 (ja) 2016-08-24 2021-01-29 黄斑変性症を治療するための医薬の製造におけるエンタカポン関連化合物の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021013670A Active JP7116202B2 (ja) 2016-08-24 2021-01-29 黄斑変性症を治療するための医薬の製造におけるエンタカポン関連化合物の使用

Country Status (7)

Country Link
US (1) US10980766B2 (https=)
EP (1) EP3503883B1 (https=)
JP (2) JP6898429B2 (https=)
CN (1) CN109689042B (https=)
AU (1) AU2017317129B2 (https=)
CA (1) CA3034547C (https=)
WO (1) WO2018036498A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10532976B2 (en) * 2015-06-23 2020-01-14 National Institute Of Biological Sciences, Beijing FTO inhibitors
AU2017317129B2 (en) * 2016-08-24 2020-04-30 National Institute Of Biological Sciences, Beijing Entacapone-related compounds to treat macular degeneration
US11103552B2 (en) 2018-05-10 2021-08-31 Regeneron Pharmaceuticals, Inc. High concentration VEGF receptor fusion protein containing formulations
CN118718181A (zh) 2019-06-05 2024-10-01 里珍纳龙药品有限公司 用于精确剂量递送的装置及方法
CN116963727A (zh) * 2020-11-13 2023-10-27 普莱克斯医药公司 用于治疗眼部病症的药剂
US20250074894A1 (en) * 2021-04-15 2025-03-06 Brown University Nitrophenyl-acrylamides and uses thereof
AU2023312773A1 (en) * 2022-07-29 2025-03-13 Rpxds Co., Ltd Fto inhibitors
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
WO2025162373A1 (en) * 2024-01-30 2025-08-07 National Institute Of Biological Sciences, Beijing Electrophile-containing catechol-o-methyltransferase (comt) inhibitors for targeting the keap1/nrf2 pathway
WO2025162358A1 (en) * 2024-01-30 2025-08-07 Rpxds Co., Ltd Fto inhibitors of bicyclic structures

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI864875A0 (fi) 1986-11-28 1986-11-28 Orion Yhtymae Oy Nya farmakologiskt aktiva foereningar, dessa innehaollande kompositioner samt foerfarande och mellanprodukter foer anvaendning vid framstaellning av dessa.
US20060034937A1 (en) * 1999-11-23 2006-02-16 Mahesh Patel Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
TW200817315A (en) * 2006-06-16 2008-04-16 Sanol Arznei Schwarz Gmbh Entacapone-derivatives
EP1946756A1 (en) * 2007-01-17 2008-07-23 Revotar Biopharmaceuticals AG Use of entacapone in cosmetic, dermatological and pharmaceutical compositions
EP1978014A1 (en) 2007-04-02 2008-10-08 Esteve Quimica, S.A. Process for the preparation of entacapone and intermediates thereof
KR101760139B1 (ko) * 2007-06-29 2017-07-31 클라렌슈 피티와이 리미티드 안투여를 통한 신경 또는 신경정신 장애의 치료 또는 예방용 약학 조성물
WO2009129497A2 (en) * 2008-04-18 2009-10-22 Arizona Board Of Regents, A Body Corp. Of The State Of Arizona, Acting For And On Behalf Of The University Of Arizona Methods and compositions for treating and identifying compounds to treat age-related macular degeneration
KR20110071064A (ko) * 2008-08-19 2011-06-28 크놉 뉴로사이언시스 인코포레이티드 (ｒ)-프라미펙솔을 사용하는 조성물 및 방법
EP2558103A4 (en) * 2010-04-12 2013-09-25 R Tech Ueno Ltd PHARMACEUTICAL COMPOSITION FOR TREATING A MACULAR DERM
WO2012142039A1 (en) * 2011-04-15 2012-10-18 University Of North Dakota Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases
ES2858511T3 (es) * 2012-10-17 2021-09-30 Exonate Ltd Compuestos útiles para tratar neovascularización ocular
CN103845317B (zh) 2012-11-28 2018-05-08 北京生命科学研究所 恩他卡朋在预防或治疗肥胖等代谢综合征中的应用
WO2015095257A2 (en) * 2013-12-18 2015-06-25 Emory University Managing visual dysfunction or loss of vision for diabetic subjects
WO2016123577A1 (en) * 2015-01-30 2016-08-04 Lieber Institute For Brain Development Comt inhibiting methods and compositions
WO2016123576A1 (en) * 2015-01-30 2016-08-04 Lieber Institute For Brain Development Comt inhibiting methods and compositions
EP3885337B1 (en) 2015-06-23 2025-01-15 National Institute Of Biological Sciences, Beijing Fto inhibitors
AU2017317129B2 (en) 2016-08-24 2020-04-30 National Institute Of Biological Sciences, Beijing Entacapone-related compounds to treat macular degeneration

Similar Documents

Publication Publication Date Title
JP2019526561A5 (https=)
Crash-2 Collaborators The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial
CN114008035A (zh) 一种shp2磷酸酶变构抑制剂
Szaliński et al. Fusarium keratitis—review of current treatment possibilities
JP2018521092A5 (https=)
Alkeswani et al. Treatment of tinea capitis
Roy et al. The potential of HIV-1 nanotherapeutics: from in vitro studies to clinical trials
JP2007513190A5 (https=)
JP2011528713A5 (https=)
JP2019515908A5 (https=)
CN109952304A (zh) 一类抑制并降解cdk的化合物
JP2020523356A5 (https=)
JP2018521007A5 (https=)
RU2018101473A (ru) Депо-препарат, содержащий сложный эфир лимонной кислоты
Borgia et al. Prophylaxis of ocular infection in the setting of intraocular surgery: implications for clinical practice and risk management
ES2405323T3 (es) Tratamiento de melanoma
JP2018138596A5 (https=)
ES2924728T3 (es) Derivados de carbazol para el tratamiento de enfermedades fibróticas, así como de síntomas y afecciones relacionados con las mismas
JP2020510045A5 (https=)
Zhang et al. Noncovalent bile acid oligomers as facial amphiphilic antimicrobials
CA2608163A1 (en) Hydralazine compositions and methods
CN110461329A (zh) 治疗血癌的PPARγ激动剂
JP2019501957A5 (https=)
RU2008108175A (ru) Комбинация соединений, которые можно использовать при лечении респираторных заболеваний, особенно хронической оструктивной болезни легких (copo) и астмы
TR200103144T2 (tr) Yeni bileşikler